Drugs / CARC-101C
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT06546436 Comparator | Aug 2024 → Nov 2025 overdue | type 1 diabetes mellitus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARC-101C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546436 ↗ |
| Modality | Cell therapy | “3×1010 eRBC(engineered Red Blood Cells)” NCT06546436 ↗ |
| Route | Other | “one-dose injection of CARC-101C” NCT06546436 ↗ |